UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-QSB
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended: August 31, 2004                   Commission File Number 000-49908

CYTODYN, INC.
(Exact name of small business issuer as specified in its charter)

COLORADO                                     75-3056237
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

200 W. DeVargas Street, Suite 1, Santa Fe, New Mexico       87501
(Address of principal executive offices)                  (Zip code)

Check whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes   X     No

Indicate the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date.

Common stock, no par value                           8,069,307

Class                     Number of shares outstanding at October 5, 2004

Transitional Small Business Disclosure Format:       Yes         No   X

This document is comprised of 11 pages.

INDEX

PART 1 - FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed balance sheet, August 31, 2004 (unaudited).................3
Condensed statements of operations, three months ended
August 31, 2004 (unaudited) and 2003 (unaudited), and October 28,
2003 (inception) through August 31, 2004 (unaudited)...............4
Condensed statements of cash flows, three months ended
August 31, 2004 (unaudited) and 2003 (unaudited) and October 28,
2003 (inception) through August 31, 2004 (unaudited)..............5
Notes to condensed financial statements (unaudited)..............6
CytoDyn, Inc. (A Development Stage Company)

Condensed Balance Sheet
(Unaudited)
August 31, 2004

<table>
<thead>
<tr>
<th>Assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Assets:</td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$76,435</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>$9,854</td>
</tr>
<tr>
<td>Total current assets</td>
<td>$86,289</td>
</tr>
<tr>
<td>Property and equipment, less accumulated depreciation</td>
<td>$6,006</td>
</tr>
<tr>
<td>Deposit</td>
<td>$495</td>
</tr>
<tr>
<td>Total assets</td>
<td>$92,790</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Shareholders' Deficit</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities:</td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$132,084</td>
</tr>
<tr>
<td>Accrued liabilities</td>
<td>$9,327</td>
</tr>
<tr>
<td>Indebtedness to related parties (Note 2)</td>
<td>$71,694</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>$213,105</td>
</tr>
<tr>
<td>Commitments and contingencies (Note 6)</td>
<td>--</td>
</tr>
</tbody>
</table>

| Shareholders' deficit (Note 4): | |
| Preferred stock, no par value; 5,000,000 shares authorized, -0- shares issued and outstanding | -- |
| Common stock, no par value; 25,000,000 shares authorized, 8,069,307 shares issued and outstanding | $1,916,334 |
| Additional paid-in capital | $24,014 |
| Accumulated deficit | $(1,601,912) |
| Deficit accumulated during development stage | $(458,751) |
| Total shareholders' deficit | $(120,315) |
| | $92,790 |
CYTODYN, INC.
(A Development Stage Company)
Condensed Statements of Operations
(Unaudited)

For the Three Months Ended
August 31, 2004
--------------------------
Through
August 31, 2003
--------------------------

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>General and administrative (Note 8)</td>
<td>$ 120,409</td>
<td>$ 5,043</td>
</tr>
<tr>
<td>Depreciation</td>
<td>292</td>
<td>--</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>120,701</td>
<td>5,043</td>
</tr>
<tr>
<td>Operating loss</td>
<td>(120,701)</td>
<td>(5,043)</td>
</tr>
<tr>
<td>Interest income</td>
<td>176</td>
<td>--</td>
</tr>
<tr>
<td>Interest expense</td>
<td>(182)</td>
<td>--</td>
</tr>
<tr>
<td>Loss before income taxes</td>
<td>(120,707)</td>
<td>(5,043)</td>
</tr>
<tr>
<td>Income tax provision (Note 5)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Net loss</td>
<td>$ (120,707)</td>
<td>$ (5,043)</td>
</tr>
<tr>
<td>Basic and diluted loss per share</td>
<td>$ (0.01)</td>
<td>$ (0.00)</td>
</tr>
<tr>
<td>Basic and diluted weighted average common shares outstanding</td>
<td>8,069,307</td>
<td>5,362,640</td>
</tr>
</tbody>
</table>

Net cash used in operating activities ..... $ (107,874) $ (5,043) $(464,769)
Cash flows from investing activities:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount 1</th>
<th>Amount 2</th>
<th>Amount 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Property and equipment purchases</td>
<td>(3,167)</td>
<td>--</td>
<td>(6,502)</td>
</tr>
<tr>
<td>Net cash used in investing activities</td>
<td>(3,167)</td>
<td>--</td>
<td>(6,502)</td>
</tr>
</tbody>
</table>

Cash flows from financing activities:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount 1</th>
<th>Amount 2</th>
<th>Amount 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital contributions by president (Note 2)</td>
<td>512</td>
<td>4,500</td>
<td>512</td>
</tr>
<tr>
<td>Proceeds from notes payable issued to related parties (Note 2)</td>
<td>--</td>
<td>--</td>
<td>111,194</td>
</tr>
<tr>
<td>Repayment of notes payable to related parties (Note 2)</td>
<td>--</td>
<td>--</td>
<td>(50,000)</td>
</tr>
<tr>
<td>Proceeds from the sale of common stock (Note 4)</td>
<td>--</td>
<td>--</td>
<td>540,000</td>
</tr>
<tr>
<td>Payment of offering costs (Note 4)</td>
<td>--</td>
<td>--</td>
<td>(54,000)</td>
</tr>
<tr>
<td>Net cash provided by financing activities</td>
<td>512</td>
<td>4,500</td>
<td>547,706</td>
</tr>
</tbody>
</table>

Net change in cash:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount 1</th>
<th>Amount 2</th>
<th>Amount 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net change in cash</td>
<td>(110,529)</td>
<td>(543)</td>
<td>76,435</td>
</tr>
</tbody>
</table>

Cash, beginning of period:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount 1</th>
<th>Amount 2</th>
<th>Amount 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash, beginning of period</td>
<td>186,964</td>
<td>3,238</td>
<td>--</td>
</tr>
</tbody>
</table>

Cash, end of period:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount 1</th>
<th>Amount 2</th>
<th>Amount 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash, end of period</td>
<td>$ 76,435</td>
<td>$ 2,695</td>
<td>$ 76,435</td>
</tr>
</tbody>
</table>

Supplemental disclosure of cash flow information:

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount 1</th>
<th>Amount 2</th>
<th>Amount 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income taxes</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Interest</td>
<td>$ 182</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

See accompanying notes to condensed financial statements
During the three months ended August 31, 2004, the Company's president paid administrative expenses on behalf of the Company totaling $4,500. The payment has been recorded as contributed capital and is included in the accompanying condensed financial statements as "Additional paid-in capital".

Note 3: Income taxes

The Company records its income taxes in accordance with SFAS No. 109, "Accounting for Income Taxes". The Company incurred net operating losses for all periods presented resulting in a deferred tax asset, which was fully allowed for by a valuation allowance; therefore, the net benefit and expense resulted in $0 income taxes.

Part I. Item 2. Management's Discussion and Analysis or Plan of Operation

CYTODYN, INC.

(A Development Stage Company)

Plan of Operation

During the next 12 months, our objectives are:

- To continue our clinical trials of Cytolin,
- To continue our efforts to protect our technology by obtaining additional patents in The United Kingdom and the European Union,
- To develop an established market for our shares, and raise funds to support our research and development efforts, the clinical trials relating to Cytolin, and our general and administrative expenses, and
- To explore joint venture arrangements for other possible pharmaceutical products.

Continuing Clinical Trials. Phase I clinical trials were conducted by Symbion Research International under the sponsorship of Amerimmune, Inc. during 2002. We believe that the data from these trials support approval by the FDA of Phase II trials, and we intend to seek approval for the Phase II trials. We will work with Symbion International and their Phase I trial data and we plan to submit our application for approval of Phase II/III pivotal studies. If the Phase II/III study is approved, we expect it, together with the pre-Phase II/III efforts, to cost an estimated $2,050,000 to $3,350,000, plus estimated manufacturing and supply costs of $350,000 to $400,000. These trials can take anywhere from 29 to 42 months. Until we have met with the FDA, which we plan to do within the next 6 months, we cannot be certain what additional studies, assuming that Phase II/III study supports the efficacy and safety of Cytolin, will be required to receive marketing approval.

If we are unable to complete clinical trials on a timely basis, with favorable results, our costs will increase significantly and we may not have enough capital to support further research and development and continue in business. Also, if we incur significant delays in being able to market our product, even if we are ultimately able to do so, we will be delayed in earning revenues and probably will require additional financing to continue in business.

Patents

During fiscal year 2004, several European patents were granted with respect to our technology. The new patents are covered by our License Agreement with Allen D. Allen, our president. These patents are designated European Patent No. 94912826.8, for the United Kingdom, Germany, France, Switzerland, Italy, the Netherlands, Portugal, Spain, and Sweden, and are the counterparts to our United States Patent No. 5424066. Patents are pending in those same countries which, if granted, will be the equivalent of our United States Patent No. 5651970. We estimate the costs associated with these pending patents to be approximately $65,000, including amounts we have already spent. We may file additional patents...
during the current fiscal year if our research and development efforts warrant them, but we do not have any such potential patents identified at this time.

Litigation

For a thorough discussion of our pending litigation, please see the section entitled "Legal Proceedings." In Part 2 Item 1.

We were plaintiffs in two pending cases, CytoDyn of New Mexico, Inc. et. al., v. Amerimmune Pharmaceuticals, Inc. et al., Case number BC290154 and the other in Ventura County, in a case captioned CytoDyn, Inc., et al. v. Amerimmune, Inc. et al., Case number SC039250., each involving our rights to the patented technology underlying Cytolin and any other products we might wish to develop.

Establishing a Market and Obtaining Funding

We will require funding during the 2005 fiscal year in order to continue our research and development efforts and to stay in business. The amount of that funding is directly related to the clinical trials we are able to conduct and the amounts we will need for our company operations.

We filed a registration statement on Form SB-2 on June 1, 2004, covering the sale of 250,000 shares of common stock at $0.75 per share, for total proceeds of $187,500, to be used primarily for general and administrative expense, SEC compliance costs, and legal and accounting fees. This registration statement has not yet gone effective, and we cannot assure that it will or that the shares that would be offered would sell. We intend, if this offering does go effective and if the shares sell, to seek an established market for our securities on an established quotation system, such as the NASD over-the-counter bulletin board, which we hope would give us a wider base of investors. We may not, however, be able to achieve our goals.

In connection with our private placement of securities in late 2003 and early 2004, we granted certain registration rights to the purchasers of our common stock and to our financial representative. The holders of these shares may demand that we register their shares for sale. We estimate that such a registration could cost us approximately $30,000, for which we would have to find funding.

In addition to operating funds, we will need from approximately $750,000 to $3,750,000 for research and development, including clinical trials, and manufacturing and supply costs, depending upon whether we are approved by the FDA to conduct a Phase II/III pivotal study.

We do not have any of this funding arranged or secured, and we do not yet have plans for raising the funding we require. We anticipate that we will seek the funding through further equity offerings, either by private placement or by registered offering, or by possible joint venture arrangements with other parties. If we are unable to secure the necessary funding, we will not be able to conduct our research and development activities or to continue in business.

Exploring Joint Ventures

While we continue to pursue FDA approval of our Cytolin product, we are also considering entering into joint ventures to develop other types of products. We have, for instance, entered into a nondisclosure agreement with another development stage biotech company to discuss the possibility of the joint development of drugs to treat neuropsychiatric diseases or disorders. These discussions are in the early stages and we do not know if we will enter into a joint venture or other arrangement with this company or if any products might ensue from our efforts.

We may also pursue joint ventures or other arrangements to obtain funding for our Cytolin-related endeavors, but we have not pursued this possibility and do not have any prospects at this time.

Other Matters

We do not expect, in the next 12 months, to make any significant expenditures for equipment, nor do we expect to make any significant changes in the number of employees that we have. We have no off-balance sheet arrangements.
Part I. Item 3. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

We maintain controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Based upon their evaluation of those controls and procedures performed within 90 days of the filing date of this report, our chief executive officer and the chief financial officer concluded that our disclosure controls and procedures were adequate.

(b) Changes in internal controls

There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of the evaluation of those controls by the chief executive officer and chief financial officer.

Part 2. Other Information

Item 1 - Legal Proceedings.

CytoDyn, Inc., v. Amerimmune, Inc. et al., Los Angeles Superior Court
Case No. BC 290154.

The court dismissed the case stating that our attorney did not present the evidence in an orderly and logical fashion. We may appeal this decision if it is cost effective in comparison to our other remedies available to us. The officer and directors of CytoDyn of New Mexico will continue to defend the cross-complaint. Management believes the cross-complaint is without merit and chances of an unfavorable outcome are remote.

CytoDyn, Inc., et al. v. Amerimmune, Inc. et al., Case number SC039250,
California Superior Court in and for the County of Ventura.

The principal relief sought was a declaration that the license granted and the assignment of the technology, patents and drug application made pursuant to the Conditional License Agreement were terminated no later than September 12, 2001, and that Allen and we are the owners of the technology, patents and investigational new drug application, free of any claims of the defendants. Costs, attorney's fees, and other "just and proper" relief also were sought.

This case was decided in favor of the plaintiffs, CytoDyn and Allen, on October 4, 2004 and the plaintiffs were awarded the declaratory relief sought and attorneys' fees.

Symbion Research International, Inc., v. Amerimmune, Inc. et al., Case number SC035668, California Superior Court in and for the County of Ventura.

We were not a party to this action; however the action affects intellectual property which is important to us.
A default was entered against Amerimmune, Inc. on December 18, 2003. A judgment was entered in favor of Symbion International on September 17, 2004 granting the declarative relief sought.

The intellectual property generated in the early phase FDA clinical trials is necessary to obtain approval for, and to conduct, further FDA clinical tests of Cytolin. Because a satisfactory result was obtained in this action, we anticipate negotiating an agreement with Symbion that will allow the use in subsequent phases of clinical test of Cytolin of the research data generated in the early phases.

Item 2 - Changes in Securities and Small Business Issuer Purchases of Equity Securities.

No response required.

Item 3 - Defaults Upon Senior Securities.

No response required.

Item 4 - Submission of Matters to a Vote of Security Holders.

No response required.

Item 5 - Other Information.

No response required.

Item 6 - Exhibits and Reports on Form 8-K.

(a) Exhibits:

1. 31.1: Certification by the CEO
2. 31.2: Certification by the CFO
3. 32.1: Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - CEO
4. 32.2: Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - CFO

(b) Reports on Form 8-K:

None.

SIGNATURES

The financial information furnished herein has not been audited by an independent accountant; however, in the opinion of management, all adjustments (only consisting of normal recurring accruals) necessary for a fair presentation of the results of operations for the three months ended August 31, 2004 have been included.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CYTODYN, INC.
(Registrant)

DATE: October 12, 2004
BY: /s/ Allen D. Allen
----------------
Allen D. Allen
CERTIFICATION

I, Allen D. Allen, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of CytoDyn, Inc.

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

   a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including any consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   d) Disclosed in this report any change in the small business issuer's internal control of financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect the small business issuer's internal control over financial reporting; and

5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):

   a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

   b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: October 12, 2004

/s/ Allen D. Allen

Allen D. Allen
Chief Executive Officer
CERTIFICATION

I, Wellington A. Ewen, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of CytoDyn, Inc.

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

   a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including any consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   d) Disclosed in this report any change in the small business issuer's internal control of financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect the small business issuer's internal control over financial reporting; and

5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):

   a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

   b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: October 12, 2004

/s/ Wellington A. Ewen

Wellington A. Ewen
Chief Financial Officer
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CytoDyn, Inc. (the "Company") on Form 10-QSB for the period ending August 31, 2004, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Allen D. Allen, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Allen D. Allen
-----------------------------
Allen D. Allen
Chief Executive Officer
October 12, 2004
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CytoDyn, Inc. (the "Company") on Form 10-QSB for the period ending August 31, 2004, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Wellington A. Ewen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Wellington A. Ewen
Wellington A. Ewen
Chief Financial Officer
October 12, 2004